ECO 2026: Meta-Analysis Links Obesity Drugs to Lower Blood Pressure Tags Hypertension GLP-1 agonists Read more about ECO 2026: Meta-Analysis Links Obesity Drugs to Lower Blood Pressure
ECO 2026: Women Using Semaglutide Showed Reduced Triptan Use Tags GLP-1 agonists Read more about ECO 2026: Women Using Semaglutide Showed Reduced Triptan Use
ECO 2026: GLP-1 Therapy Linked to Fewer Asthma Exacerbations Tags GLP-1 agonists Read more about ECO 2026: GLP-1 Therapy Linked to Fewer Asthma Exacerbations
ECO 2026: New Consensus Guidance Issued for Incretin-Based Obesity Treatment Tags GLP-1 agonists Read more about ECO 2026: New Consensus Guidance Issued for Incretin-Based Obesity Treatment
ECO 2026: GLP-1-Based Obesity Therapy Reduced Fat More Than Muscle Mass Tags GLP-1 agonists Read more about ECO 2026: GLP-1-Based Obesity Therapy Reduced Fat More Than Muscle Mass
AID Increased Time in Range in Diabetes With Advanced CKD Tags Diabetic Nephropathy hBA1c Insulin Pumps Others Delivery devices Continuous glucose monitoring (CGM) Read more about AID Increased Time in Range in Diabetes With Advanced CKD
ECO 2026: Semaglutide Reduced BMI in Severe Youth Obesity Tags GLP-1 agonists Read more about ECO 2026: Semaglutide Reduced BMI in Severe Youth Obesity
ECO2026: Continued Tirzepatide Therapy Preserves Weight Loss Tags GLP-1 agonists Read more about ECO2026: Continued Tirzepatide Therapy Preserves Weight Loss
Bexagliflozin Shows Comparable Efficacy to Most SGLT2 Inhibitors in T2DM Tags SGLT-2 Inhibitor Read more about Bexagliflozin Shows Comparable Efficacy to Most SGLT2 Inhibitors in T2DM
ECO 2026: Oral Orforglipron Maintains Weight Loss After GLP-1 Switch Tags GLP-1 agonists Read more about ECO 2026: Oral Orforglipron Maintains Weight Loss After GLP-1 Switch